Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bates

Showing results (291-300 of 430) with videos related to

Pageof 43
Sort By:
Annals of Neurology|August 2, 2003
Minocycline and doxycycline are not beneficial in a model of Huntington's diseaseDonna L Smith, Benjamin Woodman, Amarbirpal Mahal, et al.
BMJ Open|July 25, 2016
Individual placement and support (IPS) for patients with offending histories: the IPSOH feasibility cluster randomised trial protocolN Khalifa, E Talbot, J Schneider, et al.
Scientific Reports|May 4, 2017
The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patientsAndreas Neueder, Christian Landles, Rhia Ghosh, et al.
The European Journal of Neuroscience|September 30, 2005
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's diseaseEugenia Papalexi, Anna Persson, Maria Björkqvist, et al.
Neurobiology of Disease|July 17, 1998
Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat lengthM W Becher, J A Kotzuk, A H Sharp, et al.
The Journal of Biological Chemistry|June 2, 2011
Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXATina C Albershardt, Bethany L Salerni, Ryan S Soderquist, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 7, 1999
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutationR J Carter, L A Lione, T Humby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignanciesJ P Braybrooke, E Boven, N P Bates, et al.
Neurobiology of Disease|April 20, 2005
A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's diseaseTodd W Miller, Chun Zhou, Silvia Gines, et al.
Lancet (London, England)|December 17, 1983
Threat to medical confidentialityJ Barnes, P Bates, S Biddell, et al.
Pageof 43

Showing results (291-300 of 430) with videos related to

Sort By:
Pageof 43
Annals of Neurology|August 2, 2003
Minocycline and doxycycline are not beneficial in a model of Huntington's diseaseDonna L Smith, Benjamin Woodman, Amarbirpal Mahal, et al.
BMJ Open|July 25, 2016
Individual placement and support (IPS) for patients with offending histories: the IPSOH feasibility cluster randomised trial protocolN Khalifa, E Talbot, J Schneider, et al.
Scientific Reports|May 4, 2017
The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patientsAndreas Neueder, Christian Landles, Rhia Ghosh, et al.
The European Journal of Neuroscience|September 30, 2005
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's diseaseEugenia Papalexi, Anna Persson, Maria Björkqvist, et al.
Neurobiology of Disease|July 17, 1998
Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat lengthM W Becher, J A Kotzuk, A H Sharp, et al.
The Journal of Biological Chemistry|June 2, 2011
Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXATina C Albershardt, Bethany L Salerni, Ryan S Soderquist, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 7, 1999
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutationR J Carter, L A Lione, T Humby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignanciesJ P Braybrooke, E Boven, N P Bates, et al.
Neurobiology of Disease|April 20, 2005
A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's diseaseTodd W Miller, Chun Zhou, Silvia Gines, et al.
Lancet (London, England)|December 17, 1983
Threat to medical confidentialityJ Barnes, P Bates, S Biddell, et al.
Pageof 43